儿童重症监护病房中脓毒症及脓毒症急性肾脏损伤的临床研究
|
摘要
第一部分儿童重症监护室中脓毒症患儿发病情况调查
目的为了了解儿童重症监护病房PICU脓毒症的发病特点。
方法对2011年4月1日至2011年7月31日入住湖南省儿童医院重症监护病房二区的1月至18周岁之间的脓毒症患儿作为研究对象。按照脓毒症诊断标准筛选病例,符合诊断标准者均纳入研究,对其临床特点、各检查结果及预后的变化,进行分析。
结果本实验共纳入109例脓毒症患儿,其中普通脓毒症占53.2%,严重脓毒症占30.6%,脓毒症休克者为16.2%。男性占64.9%,女性占35.1%,男女之比为1.85：1。所有患儿中,18%来自城市,82%来自农村。年龄最小者30天,最大者10岁,中位数年龄为294天,1月至3月龄者占17.1%,3月至6月龄者有15.3%,6月龄至1岁者占23.4%,1岁内患儿累计占55.9%,1岁至2岁患儿占31.2%。66例有病原学培养结果：血培养阳性者16例(14.7%),其中9例为革兰氏阴性菌感染,7例(45.9%)为革兰氏阳性菌感染。痰培养阳性者59例(54.1%),其中最常见的是肺炎克雷伯杆菌(12例)及肺炎链球菌(10例)。其原发病灶最常见的为呼吸系统疾病,占64.9%,其次为颅内感染及败血症。脓毒症的死亡率为21.6%,其死亡率及总费用随着脓毒症的严重程度的增加呈上升趋势。而死亡组与存活组比较,虽总费用并无显著差异,但前者住院时间较后者短,日平均费用明显增加(P=0.005)。经多因素回归分析发现,重症脓毒症不良预后的危险因素包括：PCIS评分、降钙素原、PF比值、胱抑素C。
结论1.脓毒症在PICU中非常常见,以婴幼儿为主,主要病因为呼吸系统疾病。体液培养以革兰氏阴性菌为主。血培养阳性率低,痰培养阳性率较高。2.脓毒症患儿的死亡率及总费用均随着脓毒症的严重程度呈上升趋势,死亡患儿的日平均费用较存活组明显增高。3. PCIS评分、降钙素原、PF比值、胱抑素c是脓毒症死亡相关危险因素。
第二部分儿童重症监护病房中脓毒症急性肾损伤的临床观察
目的为了了解湖南省儿童医院重症监护病房中(PICU)脓毒症AKI患儿临床特点及其检查指标的变化,通过比较脓毒症AKI组及脓毒症非AKI组临床资料、预后等,探讨其异同点。
方法观察自2011年4月1日至2011年7月31日期间入住PICU的30天至18岁的脓毒症患儿,建立统一的调查表,自患儿入ICU至其出院第28天或死亡当日作为观察时间。入PICU时,入住PICU第3天及第7天留取患儿血、尿标本送检。按照急性肾损伤网络(AKIN)制定的AKI诊断标准,将其分为脓毒症AKI组及脓毒症非AKI组。每日观察患儿病情,所有资料如实填入统一调查表。
结果纳入的109例患儿中,其中17例因缺乏36-48小时血肌酐值而无法判断其肌酐变化。余下92例患者以肌酐变化作为诊断标准诊断AKI患儿32例(34.78%)。其中因尿少诊断为AKI者仅1例。而脓毒症、严重脓毒症及脓毒症休克患者其AKI的发病率分别为：19.15%(9/47),30%(9/30),93.3%(14/15)。随着脓毒症严重程度的增加,其发病率明显上升,其OR值为4.414(95%的可信区间为1.737-11.216),提示脓毒症是AKI发生的独立危险因素。各组的死亡率分别为2.12%(1/47),23.3%(7/30),46.7%(7/15)。所有AKI患儿中,AKI1期者8例,AKI2期者11例,AKI3期者13例。将脓毒症AKI组(32例)与脓毒症非AKI组(60例)进行比较,其性别、城乡、血培养、痰培养、其他培养及尿常规值之间无明显差异。而两组间预后、进行机械通气的人数及脓毒症严重程度之间有显著性差异。两组间比较,其PCIS评分、第3d血肌酐值、入院时尿素氮、心肌酶(肌酸激酶及其同工酶、乳酸脱氢酶)、血小板、降钙素原、碳酸氢根及二氧化碳分压之间均有显著性差异。脓毒症AKI组住PICU时间、总费用也较脓毒症非AKI组明显增加,均有显著差异。而住院时间、平均日费用及其他临床检查指标间均无明显差异。
结论根据脓毒症急性肾损伤诊断标准,脓毒症急性肾损伤的发病率为34.78%。脓毒症AKI的发生率及死亡率随着病情严重程度及脓毒症的严重程度的增加呈上升趋势。脓毒症AKI与脓毒症非AKI组比较,其住PICU时间及总费用明显增加,所需的医疗资源投入明显增多。两者临床检查资料多个指标也有明显差异,肾损伤与其他脏器损伤之间有密切联系,提示多脏器功能损伤的机制可能相似。
第三部分脓毒症肾损伤相关指标间的联系
目的探讨早期诊断AKI生物标记物CysC, KIM-1, NGAL与脓毒症AKI诊断及其预后的关系。
方法本研究选择2011年4月1日至2011年7月31日入住湖南省儿童医院重症监护病房二区的1月至18周岁之间的脓毒症患儿作为研究对象。按照脓毒症及急性肾损伤的诊断标准筛选病例,纳入研究者分为脓毒症AKI组和脓毒症非AKI者。通过观察比较Cys C、KIM-1及NGAL等指标在脓毒症AKI的诊断及其预后等方面的特点。分析其诊断能力及预测能力。
结果经过分析比较发现在脓毒症AKI诊断方面,Cys C、KIM-1、血NGAL及尿NGAL水平均在入院时即有明显升高,较血肌酐更早的预测脓毒症AKI的发生,此外,以上指标在预测脓毒症AKI预后方面也是比较好的指标。Cys C诊断脓毒症AKI的ROC曲线下面积(AUC)分别为0.927,cutoff值为1.045,超过此值时诊断为脓毒症AKI的敏感度为86.5%,特异度为93.8%。在预测脓毒症AKI的预后方面,其AUC高达0.815,Cutoff值为2.805mg/l,超过此值时其敏感度及特异度分别为80%,83.1%。尿KIM-1诊断脓毒症AKI的AUC0.852,其Cutoff值为20.47ng/l,超过此值时诊断为脓毒症AKI的敏感度高达90.7%,特异度72.5%。其预测脓毒症AKI的ROC曲线下面积为0.799(95%CI为0.687-0.910,P<0.001)。Cutoff值为33.4ng/l,此时敏感度及特异度分别为76.9%、72.9%。血NGAL (pNGAL)诊断及预测脓毒症AKI的AUC分别为0.931、0.815,两者的Cutoff值分别为63.61pg/ml及134.61pg/ml,超过此值时诊断为脓毒症AKI的敏感度高达87.5%,特异度86.6%,预测其预后的敏感度及特异度分别为85.7%,66.2%。尿NGAL (uNGAL)诊断及预测脓毒症AKI的AUC分别为0.906、0.808,两者的Cutoff值分别为65.88pg/ml,80.37pg/ml,超过此值时诊断为脓毒症AKI的敏感度高达74.2%,特异度为96.8%,预测其预后的敏感度及特异度分别为83.3%,86%。各指标与第3天血肌酐值呈不同程度的正相关(相关系数自0.330至0.585,P<0.05),比较发现血检结果与血肌酐的相关性较尿检结果更高,前者多为肾小球功能,而后者多反映的是肾小管功能。综合分析比较后发现各指标在脓毒症的诊断及预测方面各有优点。
结论脓毒症肾损伤在儿童重症监护室中的发病率高,肌酐及尿量作为其诊断指标敏感性低。胱抑素C、尿KIM-1、血尿NGAL均可作为AKI的早期诊断指标,较血肌酐可提前36h。且与脓毒症AKI的预后有关。各指标与第3天血肌酐均呈显著正相关。血检结果与尿检结果具有差异,AKI也应从肾小球功能、肾小管功能等多方面阐述。
Part Ⅰ:The clinical observation of sepsis in pediatric intensive care unit
Objective
The consistent data about the incidence and outcome of sepsis in pediatric intensive care(PICU) are lacking in China. This study was designed to understand the clinical characteristics of sepsis in Hunan Provincial Children's Hospital PICU.
Methods
This is a Prospective cohort study performed in Hunan Provincial Children's Hospital intensive care ward Ⅱ. We prospectively followed the children (from1month to18years old) diagnosis with sepsis from April1,2011to July31,2011, until their discharge,28th day of stay or death。 For all patients we collected the following data at PICU admission:age, gender, pediatric critical illness score (PCIS), associated underlying diseases and cost. Sepsis was diagnosed according to SIRS, sepsis, severe sepsis, and septic shock creteria publiced on Pediatric Critical Care Medicine (PCCM) in2005.
Results
There were109patients,53.2%sepsis,30.6%severe sepsis and16.2%septic shock. Of these,64.9%were male, and82%from rural areas. The youngest patient was30days, and the oldest was10years old, the median age was294days. And55.9%of the children less than1-year-old. In64.9%, the infection was of respiratory origin followed by intracranial infection. There were66cases were detected with etiology culture:Blood culture was positive in16cases (14.7%), of which nine cases were Gram-negative bacteria, seven cases (45.9%) were Gram-positive bacteria. Sputum culture was positive in59cases (54.1%), Klebsiella pneumoniae (12cases) and Streptococcus pneumoniae (10cases) were the most common. Mortality rate was21.6%. The mortality and the total cost was rising with the severity of sepsis. Compared to the survival group, the average cost of the death group was significantly higher (P=0.005). Multivariate regression analysis showed that the poor prognosis (death) risk factors of severe sepsis include:the PCIS score, procalcitonin, the PO2/FiO2ratio and cystatin C.
Conclusion
Sepsis was very common in yonger children in PICU,and the main cause was respiratory diseases. The mortality and the total cost was rising with the severity of sepsis. Compared to the Survival group, the average cost of the Death group was significantly higher. Multivariate regression analysis showed that poor prognosis (death) risk factors of severe sepsis include:the PCIS score, procalcitonin, the PF ratio and cystatin C.
Part II The clinical observation of septic acute kidney injury in pediatric intensive care unit
Objectives
We conducted a study to evaluate the incidence, risk factors and outcomes associated with early acute kidney injury (AKI) in sepsis in PICU.
Methods
The study was a prospectively collected data from the Hunan Provincial Children's Hospital intensive care ward Ⅱ. We prospectively followed the children (from lmonth to18years old) diagnosis with sepsis from April1,2011to July31,2011, until their discharge,28th day of stay or death. The blood and urine specimens were collected on the1d,3d,7d after the PICU admission. AKI was diagnosed according to Acute Kidney Injury Net(AKIN). We divided the patients into septic AKI group and septic non-AKI group. The main outcome measures were clinical and laboratory data and outcomes.
Results
Of all109patients,17cases could not determine the creatinine change due to the lack of second serum creatinine. Of the92patients, there were32(34.78%) septic AKI patients according to the AKI diagnostic criteria, of which8were AKI stage1,11were stage2and13were stage3. The incidence of AKI induced by sepsis, severe sepsis and septic shock was19.15%(9/47),30%(9/30),93.3%(14/15), respectively. And the mortality of each group were2.12%(1/47),23.3%(7/30),46.7%(7/15), respectively. Sepsis were independent risk factors for AKI occurred, with the severity of sepsis, the incidence increased significantly[OR=4.414(95%confidence interval:1.737-11.216)]. We found that there are significant differences in the prognosis, PICU time, the total cost, the mechanical ventilation, sepsis severity, the PCIS score, the3d serum creatinine, blood urea nitrogen, serum creatine kinase (creatine kinase and its isoenzymes, lactate dehydrogenase), platelets, procalcitonin, bicarbonate and carbon dioxide partial pressure between the two groups.
Conclusion
The incidence rate of septic AKI was34.78%in PICU according to the diagnostic criteria of septic AKI. The mortality rate was significantly increased with the severity of sepsis. Compare to the sepsis non-AKI group, septic AKI group had a longer stay in PICU and the total costs increased significantly. There were significant differences in the clinical examination data. Sepsis AKI and other organ damage are closely linked, suggesting that the mechanism of multiple organ dysfunction may be similar.
Part Ⅲ The clinical observation of septic acute kidney injury in pediatric intensive care unit
Objectives
To investigate the relationship between the early diagnosis of AKI biomarker (cystatin C, KIM-1, NGAL) and the diagnosis and prognosis of septic AKI.
Methods
Screening cases in accordance with the diagnostic criteria for sepsis and acute kidney injury were divided to two group(septic AKI group and septic non-AKI group). Observing the characteristisc of cys C, KIM-1and NGAL in the diagnosis and the prognosis of septic AKI. Study the diagnostic capabilities and the prediction ability of each indicators.
Result
We found that the concentration of Cys C, KIM-1, NGAL was increased sinificantly at the time of PICU admission. Compare to serum crearinine, they were earlier diagnostic indicators and prognostic marker of septic AKI. The area under the curve(AUC) for reciver operationg characteristic(ROC) for Cys C-2h for prediction of septic AKI was0.927, the cutoff was1.045mg/1, The sensitivites and specificities were86.5%,93.8%, respectively. The AUC for prognosis of septic AKI was0.815. The cutoff was2.805mg/1, and the sensitivity and specificitiy were80%and83.1%, respectively. The AUC for uKIM-1for prediction of septic AKI was0.852, the cutoff was20.47ng/1, The sensitivity and specificitiy were90.7%and72.5%, respectively. The AUC for prognosis of septic AKI was0.799(95%CI:0.687-0.910, P<0.001). The cutoff was33.4ng/l, sensitivity and specificitiy were76.9%and72.9%, respectively. The AUC for pNGAL for prediction of septic AKI was0.931, the cutoff was63.61pg/ml, The sensitivity and specificitiy were87.5%and86.6%, respectively. The AUC for prognosis of septic AKI was0.815, the cutoff was134.61pg/ml, sensitivity and specificity were85.7%and66.2%, respectively. The AUC for uNGAL for prediction of septic AKI was0.906, the cutoff was65.88pg/ml. The sensitivity and specificity were74.2%and96.8%, respectively. The AUC for prognosis of septic AKI was0.808, the cutoff was80.37pg/ml, sensitivity and specificity were83.3%and86%, respectively. All of them were positively correlated with the peak serum creatinine concentration(r=0.330-0.585, P<0.05).
Conclusion
Septic AKI in pediatric intensive care unit have higher incidence rate; cys C、uKIM-1、pNGAL、uNGAL were earlier marker for diagnose and predict AKI。All of them were positively correlated with the peak serum creatinine concentration。
目的为了了解儿童重症监护病房PICU脓毒症的发病特点。
方法对2011年4月1日至2011年7月31日入住湖南省儿童医院重症监护病房二区的1月至18周岁之间的脓毒症患儿作为研究对象。按照脓毒症诊断标准筛选病例,符合诊断标准者均纳入研究,对其临床特点、各检查结果及预后的变化,进行分析。
结果本实验共纳入109例脓毒症患儿,其中普通脓毒症占53.2%,严重脓毒症占30.6%,脓毒症休克者为16.2%。男性占64.9%,女性占35.1%,男女之比为1.85：1。所有患儿中,18%来自城市,82%来自农村。年龄最小者30天,最大者10岁,中位数年龄为294天,1月至3月龄者占17.1%,3月至6月龄者有15.3%,6月龄至1岁者占23.4%,1岁内患儿累计占55.9%,1岁至2岁患儿占31.2%。66例有病原学培养结果：血培养阳性者16例(14.7%),其中9例为革兰氏阴性菌感染,7例(45.9%)为革兰氏阳性菌感染。痰培养阳性者59例(54.1%),其中最常见的是肺炎克雷伯杆菌(12例)及肺炎链球菌(10例)。其原发病灶最常见的为呼吸系统疾病,占64.9%,其次为颅内感染及败血症。脓毒症的死亡率为21.6%,其死亡率及总费用随着脓毒症的严重程度的增加呈上升趋势。而死亡组与存活组比较,虽总费用并无显著差异,但前者住院时间较后者短,日平均费用明显增加(P=0.005)。经多因素回归分析发现,重症脓毒症不良预后的危险因素包括：PCIS评分、降钙素原、PF比值、胱抑素C。
结论1.脓毒症在PICU中非常常见,以婴幼儿为主,主要病因为呼吸系统疾病。体液培养以革兰氏阴性菌为主。血培养阳性率低,痰培养阳性率较高。2.脓毒症患儿的死亡率及总费用均随着脓毒症的严重程度呈上升趋势,死亡患儿的日平均费用较存活组明显增高。3. PCIS评分、降钙素原、PF比值、胱抑素c是脓毒症死亡相关危险因素。
第二部分儿童重症监护病房中脓毒症急性肾损伤的临床观察
目的为了了解湖南省儿童医院重症监护病房中(PICU)脓毒症AKI患儿临床特点及其检查指标的变化,通过比较脓毒症AKI组及脓毒症非AKI组临床资料、预后等,探讨其异同点。
方法观察自2011年4月1日至2011年7月31日期间入住PICU的30天至18岁的脓毒症患儿,建立统一的调查表,自患儿入ICU至其出院第28天或死亡当日作为观察时间。入PICU时,入住PICU第3天及第7天留取患儿血、尿标本送检。按照急性肾损伤网络(AKIN)制定的AKI诊断标准,将其分为脓毒症AKI组及脓毒症非AKI组。每日观察患儿病情,所有资料如实填入统一调查表。
结果纳入的109例患儿中,其中17例因缺乏36-48小时血肌酐值而无法判断其肌酐变化。余下92例患者以肌酐变化作为诊断标准诊断AKI患儿32例(34.78%)。其中因尿少诊断为AKI者仅1例。而脓毒症、严重脓毒症及脓毒症休克患者其AKI的发病率分别为：19.15%(9/47),30%(9/30),93.3%(14/15)。随着脓毒症严重程度的增加,其发病率明显上升,其OR值为4.414(95%的可信区间为1.737-11.216),提示脓毒症是AKI发生的独立危险因素。各组的死亡率分别为2.12%(1/47),23.3%(7/30),46.7%(7/15)。所有AKI患儿中,AKI1期者8例,AKI2期者11例,AKI3期者13例。将脓毒症AKI组(32例)与脓毒症非AKI组(60例)进行比较,其性别、城乡、血培养、痰培养、其他培养及尿常规值之间无明显差异。而两组间预后、进行机械通气的人数及脓毒症严重程度之间有显著性差异。两组间比较,其PCIS评分、第3d血肌酐值、入院时尿素氮、心肌酶(肌酸激酶及其同工酶、乳酸脱氢酶)、血小板、降钙素原、碳酸氢根及二氧化碳分压之间均有显著性差异。脓毒症AKI组住PICU时间、总费用也较脓毒症非AKI组明显增加,均有显著差异。而住院时间、平均日费用及其他临床检查指标间均无明显差异。
结论根据脓毒症急性肾损伤诊断标准,脓毒症急性肾损伤的发病率为34.78%。脓毒症AKI的发生率及死亡率随着病情严重程度及脓毒症的严重程度的增加呈上升趋势。脓毒症AKI与脓毒症非AKI组比较,其住PICU时间及总费用明显增加,所需的医疗资源投入明显增多。两者临床检查资料多个指标也有明显差异,肾损伤与其他脏器损伤之间有密切联系,提示多脏器功能损伤的机制可能相似。
第三部分脓毒症肾损伤相关指标间的联系
目的探讨早期诊断AKI生物标记物CysC, KIM-1, NGAL与脓毒症AKI诊断及其预后的关系。
方法本研究选择2011年4月1日至2011年7月31日入住湖南省儿童医院重症监护病房二区的1月至18周岁之间的脓毒症患儿作为研究对象。按照脓毒症及急性肾损伤的诊断标准筛选病例,纳入研究者分为脓毒症AKI组和脓毒症非AKI者。通过观察比较Cys C、KIM-1及NGAL等指标在脓毒症AKI的诊断及其预后等方面的特点。分析其诊断能力及预测能力。
结果经过分析比较发现在脓毒症AKI诊断方面,Cys C、KIM-1、血NGAL及尿NGAL水平均在入院时即有明显升高,较血肌酐更早的预测脓毒症AKI的发生,此外,以上指标在预测脓毒症AKI预后方面也是比较好的指标。Cys C诊断脓毒症AKI的ROC曲线下面积(AUC)分别为0.927,cutoff值为1.045,超过此值时诊断为脓毒症AKI的敏感度为86.5%,特异度为93.8%。在预测脓毒症AKI的预后方面,其AUC高达0.815,Cutoff值为2.805mg/l,超过此值时其敏感度及特异度分别为80%,83.1%。尿KIM-1诊断脓毒症AKI的AUC0.852,其Cutoff值为20.47ng/l,超过此值时诊断为脓毒症AKI的敏感度高达90.7%,特异度72.5%。其预测脓毒症AKI的ROC曲线下面积为0.799(95%CI为0.687-0.910,P<0.001)。Cutoff值为33.4ng/l,此时敏感度及特异度分别为76.9%、72.9%。血NGAL (pNGAL)诊断及预测脓毒症AKI的AUC分别为0.931、0.815,两者的Cutoff值分别为63.61pg/ml及134.61pg/ml,超过此值时诊断为脓毒症AKI的敏感度高达87.5%,特异度86.6%,预测其预后的敏感度及特异度分别为85.7%,66.2%。尿NGAL (uNGAL)诊断及预测脓毒症AKI的AUC分别为0.906、0.808,两者的Cutoff值分别为65.88pg/ml,80.37pg/ml,超过此值时诊断为脓毒症AKI的敏感度高达74.2%,特异度为96.8%,预测其预后的敏感度及特异度分别为83.3%,86%。各指标与第3天血肌酐值呈不同程度的正相关(相关系数自0.330至0.585,P<0.05),比较发现血检结果与血肌酐的相关性较尿检结果更高,前者多为肾小球功能,而后者多反映的是肾小管功能。综合分析比较后发现各指标在脓毒症的诊断及预测方面各有优点。
结论脓毒症肾损伤在儿童重症监护室中的发病率高,肌酐及尿量作为其诊断指标敏感性低。胱抑素C、尿KIM-1、血尿NGAL均可作为AKI的早期诊断指标,较血肌酐可提前36h。且与脓毒症AKI的预后有关。各指标与第3天血肌酐均呈显著正相关。血检结果与尿检结果具有差异,AKI也应从肾小球功能、肾小管功能等多方面阐述。
Part Ⅰ:The clinical observation of sepsis in pediatric intensive care unit
Objective
The consistent data about the incidence and outcome of sepsis in pediatric intensive care(PICU) are lacking in China. This study was designed to understand the clinical characteristics of sepsis in Hunan Provincial Children's Hospital PICU.
Methods
This is a Prospective cohort study performed in Hunan Provincial Children's Hospital intensive care ward Ⅱ. We prospectively followed the children (from1month to18years old) diagnosis with sepsis from April1,2011to July31,2011, until their discharge,28th day of stay or death。 For all patients we collected the following data at PICU admission:age, gender, pediatric critical illness score (PCIS), associated underlying diseases and cost. Sepsis was diagnosed according to SIRS, sepsis, severe sepsis, and septic shock creteria publiced on Pediatric Critical Care Medicine (PCCM) in2005.
Results
There were109patients,53.2%sepsis,30.6%severe sepsis and16.2%septic shock. Of these,64.9%were male, and82%from rural areas. The youngest patient was30days, and the oldest was10years old, the median age was294days. And55.9%of the children less than1-year-old. In64.9%, the infection was of respiratory origin followed by intracranial infection. There were66cases were detected with etiology culture:Blood culture was positive in16cases (14.7%), of which nine cases were Gram-negative bacteria, seven cases (45.9%) were Gram-positive bacteria. Sputum culture was positive in59cases (54.1%), Klebsiella pneumoniae (12cases) and Streptococcus pneumoniae (10cases) were the most common. Mortality rate was21.6%. The mortality and the total cost was rising with the severity of sepsis. Compared to the survival group, the average cost of the death group was significantly higher (P=0.005). Multivariate regression analysis showed that the poor prognosis (death) risk factors of severe sepsis include:the PCIS score, procalcitonin, the PO2/FiO2ratio and cystatin C.
Conclusion
Sepsis was very common in yonger children in PICU,and the main cause was respiratory diseases. The mortality and the total cost was rising with the severity of sepsis. Compared to the Survival group, the average cost of the Death group was significantly higher. Multivariate regression analysis showed that poor prognosis (death) risk factors of severe sepsis include:the PCIS score, procalcitonin, the PF ratio and cystatin C.
Part II The clinical observation of septic acute kidney injury in pediatric intensive care unit
Objectives
We conducted a study to evaluate the incidence, risk factors and outcomes associated with early acute kidney injury (AKI) in sepsis in PICU.
Methods
The study was a prospectively collected data from the Hunan Provincial Children's Hospital intensive care ward Ⅱ. We prospectively followed the children (from lmonth to18years old) diagnosis with sepsis from April1,2011to July31,2011, until their discharge,28th day of stay or death. The blood and urine specimens were collected on the1d,3d,7d after the PICU admission. AKI was diagnosed according to Acute Kidney Injury Net(AKIN). We divided the patients into septic AKI group and septic non-AKI group. The main outcome measures were clinical and laboratory data and outcomes.
Results
Of all109patients,17cases could not determine the creatinine change due to the lack of second serum creatinine. Of the92patients, there were32(34.78%) septic AKI patients according to the AKI diagnostic criteria, of which8were AKI stage1,11were stage2and13were stage3. The incidence of AKI induced by sepsis, severe sepsis and septic shock was19.15%(9/47),30%(9/30),93.3%(14/15), respectively. And the mortality of each group were2.12%(1/47),23.3%(7/30),46.7%(7/15), respectively. Sepsis were independent risk factors for AKI occurred, with the severity of sepsis, the incidence increased significantly[OR=4.414(95%confidence interval:1.737-11.216)]. We found that there are significant differences in the prognosis, PICU time, the total cost, the mechanical ventilation, sepsis severity, the PCIS score, the3d serum creatinine, blood urea nitrogen, serum creatine kinase (creatine kinase and its isoenzymes, lactate dehydrogenase), platelets, procalcitonin, bicarbonate and carbon dioxide partial pressure between the two groups.
Conclusion
The incidence rate of septic AKI was34.78%in PICU according to the diagnostic criteria of septic AKI. The mortality rate was significantly increased with the severity of sepsis. Compare to the sepsis non-AKI group, septic AKI group had a longer stay in PICU and the total costs increased significantly. There were significant differences in the clinical examination data. Sepsis AKI and other organ damage are closely linked, suggesting that the mechanism of multiple organ dysfunction may be similar.
Part Ⅲ The clinical observation of septic acute kidney injury in pediatric intensive care unit
Objectives
To investigate the relationship between the early diagnosis of AKI biomarker (cystatin C, KIM-1, NGAL) and the diagnosis and prognosis of septic AKI.
Methods
Screening cases in accordance with the diagnostic criteria for sepsis and acute kidney injury were divided to two group(septic AKI group and septic non-AKI group). Observing the characteristisc of cys C, KIM-1and NGAL in the diagnosis and the prognosis of septic AKI. Study the diagnostic capabilities and the prediction ability of each indicators.
Result
We found that the concentration of Cys C, KIM-1, NGAL was increased sinificantly at the time of PICU admission. Compare to serum crearinine, they were earlier diagnostic indicators and prognostic marker of septic AKI. The area under the curve(AUC) for reciver operationg characteristic(ROC) for Cys C-2h for prediction of septic AKI was0.927, the cutoff was1.045mg/1, The sensitivites and specificities were86.5%,93.8%, respectively. The AUC for prognosis of septic AKI was0.815. The cutoff was2.805mg/1, and the sensitivity and specificitiy were80%and83.1%, respectively. The AUC for uKIM-1for prediction of septic AKI was0.852, the cutoff was20.47ng/1, The sensitivity and specificitiy were90.7%and72.5%, respectively. The AUC for prognosis of septic AKI was0.799(95%CI:0.687-0.910, P<0.001). The cutoff was33.4ng/l, sensitivity and specificitiy were76.9%and72.9%, respectively. The AUC for pNGAL for prediction of septic AKI was0.931, the cutoff was63.61pg/ml, The sensitivity and specificitiy were87.5%and86.6%, respectively. The AUC for prognosis of septic AKI was0.815, the cutoff was134.61pg/ml, sensitivity and specificity were85.7%and66.2%, respectively. The AUC for uNGAL for prediction of septic AKI was0.906, the cutoff was65.88pg/ml. The sensitivity and specificity were74.2%and96.8%, respectively. The AUC for prognosis of septic AKI was0.808, the cutoff was80.37pg/ml, sensitivity and specificity were83.3%and86%, respectively. All of them were positively correlated with the peak serum creatinine concentration(r=0.330-0.585, P<0.05).
Conclusion
Septic AKI in pediatric intensive care unit have higher incidence rate; cys C、uKIM-1、pNGAL、uNGAL were earlier marker for diagnose and predict AKI。All of them were positively correlated with the peak serum creatinine concentration。
引文
[1]Bone RC,Balk RA,Cem FB,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine[J].Chest.1992,101:1644-1655.
P1 Levy MM, Fink MP, Marshall JC, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference[J]. Crit Care Med.2003,31:1250-1256.
[3]Martin GS,Mannino DM,Eaton S,et al. The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med 2003,348(16):1546-1554.
[4]Vincent JL,Sakr Y Sprung CL,et al. Sepsis in European intensive care units:Results of the SOAP study[J]. Crit Care Med 2006,34(2):344-353.
[5]Adfie C, Alberti C, Chaix-Couturier C,et al. Epidemiology and economic evaluation of severe sepsis in France:age, severity,infection site, and place of acquisition(community, hospital or intensive care unit as determinants of workload and cost[J]. J Crit Care 2005,20:46-58.
[6]Sushma K,Cribbs,Greg S et al. Expanding the global epidemiology of sepsis[J]. Cfit Care Med.2007,35(11):2646-2648.
[7]Angus DC,Linde-Zwirble WT,Lidicker J,et al. Epidemiology of severe sepsis in the United States:analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med.2001,29:1303-1310.
[8]Silva E, Pedro MA, Sogaya ACB, et al:Brazilian Sepsis Epidemiological Study (BASES study) [J]. Crit Care 2004,8(4):R251-R260.
[9]Sundarrarajan V, Korman Z, Visvanathan K,et al. The microbiology and outcome of sepsis in Victoria,Australia[J]. Epidemiol Infect,2005,000:1-8.
[10]Finfer S,Bellomo L, Lipman J,et al. Adult population incidence of severe sepsis in Australia and New Zealand intensive care units[J]. Intensive Care Med.2004,30: 589-596
[11]Padkin A,Goldfrad C,Brady AR,et al. Epidemiology of severe sepsis occ urring in the first 24h in intensive care units in England, Wales and Northern Ireland[J]. Crit Care Med.2003,31:2332-2338.
[12]Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults:A multicenter prospective study in intensive care units[J]. JAMA.1995,274:968-974.
[131林洪远,盛志勇.我们需要一个更清晰的脓毒症概念和标准[J].中华外科杂志.2004,42：836-838.
[14]黎沾良.全身炎症反应综合征和多器官功能障碍综合征[J].中国实用外科杂志.1999,19(1)：36-37.
[15]柴家科,盛志勇,郭振荣等.不同治疗阶段(1970～1998年)烧伤脓毒症的防治经验[J].中华烧伤杂志.2000,16(2)：78-81.
[16]代静泓,邱海波,杨毅等.1991-2001年ICU严重感染的流行病学调查分析[J].中华老年多器官杂志.2003,2：42-46.
[17]Cheng B,Xie G Yao S,et al. Epidemiology of Severe Sepsis in Critically ill Surgical Patients in 10 University Hospitals in China[J]. Crit Care Med.2007, 35(11):2538-2546.
[18]Goldstein B,Gimir B,Randolph A,et al. International pediatric sepsis consensus conference:definitions for sepsis and organ dysfunction in pediatrics[J].Pediatric Crit Care Med.2005,6:2-8.
[19]Hayden WR. Sepsis terminology in pediatrics[J].J Pediatr.1994,124:657-658.
[20]樊寻梅,武志远.国际儿科脓毒症定义会议介绍[J].中华儿科学,2005,43：618-620.
[21]喻文亮,陆铸今,孙波.小儿、新生儿全身炎症反应综合征、脓毒症及感染性休克新定义[J].中国小儿急救医学.2006,13：1-4.
[22]R Scott Watson, Joseph, A Carcillo Walter, et al.The Epidemiology of Severe Sepsis in Children in the United States[J].Am J Resp and Crit Care Med.2003, 167:695-701.
[23]王嵩,王义,郭纪元.儿童重症监护病房脓毒症患病现状调查分析[J].陕西医学杂志[J].2009.38(1)：112-3
[24]上海ICU脓毒症诊治情况调查协作组.上海市四家儿童医院重症监护病房304例脓毒症诊治调查分析[J].中华儿科杂志,2012,50(3)：172-177。
[25]中华医学会儿科分会急诊学组.第四届全国小儿急救医学研讨会纪要[J].中华儿科杂志,1995,33：370-373
[26]WY Kim, JW Huh, CM Lim et al.A Comparison of Acute Kidney Injury Classifications in Patients With Severe Sepsis and Septic Shock[J].Am J Med Sci. 2012 Jan 18. [Epub ahead of print]
[1]Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure:a population-based study. Crit Care[J].2005,9:R700-R709.
[2]Korkeila M, Ruokonen E, Takala J.Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care[J]. Intensive Care Med.2000,26:1824-1831
[3]Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients[J]. Crit Care Med.2002, 30:2051-2058.
[4]GS, Morimatsu H, Morgera S, Schetz M, et al. Acute renal failure in critically ill patients:a multinational, multicenter study[J]. JAMA.2005,294:813-818.
[5]Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units[J]. Crit Care 2007,11:R68,1-9.
[6]Xue JL, Daniels F, Star RA,et al. Incidence and mortality of acute renal failure in Medicare beneficiaries,1992 to 2001[J]. J Am Soc Nephrol.2006,17:1135-1142.
[7]Vachvanichsanong P, Dissaneewate P, Lim A, Mcneil E. Childhood acute renal failure:22-year experience in a university hospital in southern Thailand. Pediatrics. 2006;118(3):e786-791.
[8]Andreoli SP. Acute renal failure [J]. Curr Opin Pediatr.2002,14:183-188.
[91 Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure[J]. Pediatr Nephrol.2002,17:61-69.
[10]Williams DM, Sreedhar SS, Mickell JJ, et al. Acute kidney failure:a pediatric experience over 20 years[J]. Arch Pediatr Adolesc Med.2002,156:893-900.
[11]Hui-Stickle S, Brewer ED, Goldstein SL.Pediatric ARF Epidemiology at a Teritary Care Center from 1999 to 2001 [J]. Am J Kidney Dis.2005,45:96-101.
[12]Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury[J]. Kidney Int.2007,71:1028-35.
[13]Loza R, Estremadoyro L, Loza C, et al. Factors associated with mortality in acute renal failure (ARF) in children[J]. Pediatr Nephrol.2006,21:106-9.
[14]Olowu WA, Adelusola KA. Pediatric acute renal failure in southwestern Nigeria[J]. Kidney Int.2004,66:1541-8.
[15]Bailey D, Phan V, Litalien C, et al. Risk factors of acute renal failure in critically ill children:a prospective descriptive epidemiological study [J]. Pediatr Crit Care Med.2007,8:29-35.
[16]Gallego N, Perez-Caballero C, Gallego A, et al. Prognosis of patients with acute renal failure without cardiopathy[J]. Arch Dis Child.2001,84:258-60.
[17]Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality:A prospective, multicenter study. French Study Group on Acute Renal Failure[J]. Crit Care Med. 1996:192-198.
[18]de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU:Risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000:915-921.
[19]Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States[J]. Am J Respir Crit Care Med. 2003:695-701.
[40]Bagshaw SM, George C, Dinu I,Bellomo R. A multi-centre evaluation of the Rifle criteria for early acute kidney injury in critically ill patients[J].Nephrol Dial Transplant 2008,23:1203-1210.
[21]Ostermann M, Chang RW. Acute kidney injury in the intensive care unit ACCording to RIFLE[J]. Crit Care Med.2007,35:1837-1843.
[22]Bagshaw SM, Uehino S, Bellomo R, etl.Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators:Septic acute kidney injury in critically ill patients:clinical characteristics and outcomes[J]. Clin J Am Soc Nephrol.2007,2:431-439.
[23]Lameire N, VanBiesen W, Vanholder R. Acute renal failure[J]. lancet.2005,365: 417-430.
[24]Edelstein, CL. Schrier, RW. Pathophysiology of ischemic acute renal failure[J]. In: Schrier, RW., editor.Diseases of the kidney and urinary tract.7. Vol.2. Philadelphia: Lippincott Williams & Wilkins; 2001. p1041-69.
[25]杨荣利,王小亭,刘大为.感染性休克致急性肾损伤的血流动力学特征及对预后的意义,中华内科杂志[J].2009,9：715-719.
[26]Devarajan P. Emerging biomarkers of acute kidney injury[J]. Contrib Nephrol. 2007:203-212.
[27]Goldstein SL, Currier H, Graf JM, et al. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics[J].2001:1309-1312.
[28]Goldstein SL, Somers MJG, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy [J]. Kidney Int.2005:653-658.
[29]Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children:A retrospective analysis [J]. Crit Care Med.2004:1771-1776.
[30]Lowrie LH. Renal replacement therapies in pediatric multi-organ dysfunction syndrome[J]. Pediatr Nephrol.2000:6-12.
[31]Bellomo R, Bagshaw S, Langenberg C, et al. Pre-renal azotemia:a flawed paradigm in critically ill septic patients? [J].Contrib Nephrol.2007,156:1-9
[32]Langenberg C, Wan L, Bagshaw SM, et al.Urinary biochemistry in experimental septic acute renal failure. Nephrol Dial Transplant [J].2006,21:3389-3397.
[33]Langenberg C,Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure[J].Kidney Int.2006,69:1996-2002.
[34]Licari E, Calzava P, Ronco C. Bellomo R.Fluid resuscitation and the septic kidney: the evidence[J].Contrib Nephrol.2007,156:167-177.
[35]刘娟,钱素云.小儿脓毒症和严重脓毒症发病情况单中心调查[J].2010,28(1)：26-29.
[35]Venkatachalam MA, Griffin KA, Lan R,et al. Acute kidney injury:a springboard for progression in chronic kidney disease [J]. Am J Physiol Renal Physiol.2010, 298:F1078-F1094.
[37]Askenazi DJ, Feig DI, Graham NM, et al.3-5 year longitudinal follow-up of pediatric patients after acute renal failure[J]. Kidney Int.2006,69:184-189.
[38]Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network:report of an initiative to improve outcomes in acute kidney injury[J]. Crit Care.2007,11:R31
[39]Bellomo R, Ronco C, Kellum JA, et al. Acute Dialysis Quality Initiative Workgroup:Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs [J]. Crit Care.2004,8:R204-R212.
[40]WY Kim, JW Huh, CM Lim et al.A Comparison of Acute Kidney Injury Classifications in Patients With Severe Sepsis and Septic Shock[J].Am J Med Sci. 2012 Jan 18,R700-R709.
[41]Bagshaw, S. M., S. Lapinsky, et al. Acute kidney injury in septic shock:clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy[J]. Intensive Care Med.2009,35(5):871-881.
[42]Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States:analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med.2001,29:1303-1310
[43]Martin GS, Mannino DM, Eaton S, et al.The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med.2003,348:1546-1554
[44]Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS:a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units[J]. Intensive Care Med.2004,30:580-588
[45]Lopes JA, Jorge S, Resina C, et al. Acute renal failure in patients with sepsis[J]. Crit Care.2007,11:411
[46]Yegenaga I, Hoste E, Van Biesen W, et al. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome:results of a prospective study[J]. Am J Kidney Dis.2004,43:817-824
[47]Hoste EA, Lameire NH, Vanholder RC,et al. Acute renal failure in patients with sepsis in a surgical ICU:predictive factors, incidence, comorbidity, and outcome[J]. J Am Soc Nephrol.2003,14:1022-1030
[48]Vincent JL, Sakr Y, Sprung CL, et al.Sepsis in European intensive care units: results of the SOAP study[J]. Crit Care Med.2006,34:344-353
[49]Oppert M, Engel C, Brunkhorst FM, et al.Acute renal failure in patients with severe sepsis and septic shock a significant independent risk factor for mortality: results from the German Prevalence Study [J]. Nephrol Dial Transplant.2008, 23:904-909
[50]Neveu H, Kleinknecht D, Brivet F, et al. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure[J]. Nephrol Dial Transplant.1996,11-.293-299
[1]Schneider J, Khemani R, Grushkin C, et al. Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit[J]. Crit Care Med.2010, 38:933-939.
[2]Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury [J]. Kidney Int.2007,71:1028-1035.
[3]Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL):A troponin-like biomarker for human acute kidney injury[J]. Nephrology (Carlton).2010, 15:419-428.
[4]Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease[J]. Curr Opin Nephrol Hypertens.2008,17:127-132
[5]Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol.2006,17:1503-1520.
[6]Murray PT, Devarajan P, Levey AS, et al. A framework and key research questions in AKI diagnosis and staging in different environments[J]. Clin J Am Soc Nephrol. 2008,3:864-868.
[7]Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics[J]. Kidney Int.1985,928-937.
[8]Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury[J]. Pediatr Nephrol.2008,23:2151-2157.
[9]Devarajan P. Emerging biomarkers of acute kidney injury[J], Contrib Nephrol. 2007,156:203-212.
[10]Devarajan P. Proteomics for biomarker discovery in acute kidney injury[J]. Semin Nephrol.2007,27:637-651.
[11]Devarajan P. Proteomics for the investigation of acute kidney injury[J]. Contrib Nephrol.2008,160:1-16.
[12]Prasad Devarajan. Biomarkers for the Early Detection of Acute Kidney Injury[J]. Curr Opin Pediatr.2011,23(2):194-200
[13]Brzin J, Popovic T, Turk V, et al. Human cystatin, a new protein inhibitor of cysteine proteinases[J]. Biochem Biophys Res Commun 1984,118:103-109.
[14]Barrett AJ, DaviesME,Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors[J]. Biochem Biophys Res Commun. 1984,120:631-636.
[15]Grubb AO. Cystatin C:properties and use as diagnostic marker[J]. Adv Clin Chem.2000,35:63-99.
[16]Kaseda R, Iino N, HosojimaM, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells[J]. Biochem Biophys Res Commun 2007,357:1130-1134.
[17]Herget-Rosenthal S,MarggrafG, Husing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int 2004,66:1115-1122.
[18]Bonventre JV. Kidney injury molecule-1 (KIM-1):a urinary biomarker and much more[J]. Nephrol Dial Transplant.2009,24(11):3265-3268.
[19]Michael Zappitellil, Kimberly K Washburnl, Ayse A Arikanl,et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children:a prospective cohort study[J].Critical Care,11(4):R84.
[20]Sean M. Bagshaw, Michael Bennett, Michael Haase et al.Plasma and urine neutrophil gelatinaseassociated lipocalin in septic versus non-septic acute kidney injury in critical illness[J].Intensive Care Med,2010,36:452-461
[21]Neveu H, Kleinknecht D, Brivet F,, et al. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The french study group on acute renal failure[J]. Nephrol Dial Transplant.1996,11:293-299
[22]Uchino S, Kellum JA, Bellomo R, et al.Acute renal failure in critically ill patients: a multinational, multicenter study[J]. JAMA,2005 294:813-818
[23]Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis:a multicentre evaluation[J]. Crit Care.2008,12:R47
[24]Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients:clinical characteristics and outcomes[J]. Clin J Am Soc Nephrol 2007,2:431-439
[25]Wan L, Bagshaw SM, Langenberg C, et al. Pathophysiology of septic acute kidney injury:what do we really know? [J].Crit Care Med.2008,36:S198-S203
[26]Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay and costs in hospitalized patients[J]. J Am Soc Nephrol.2005, 16:3365-3370.
[27]Price, J. F., A. R. Mott, et al. Worsening renal function in children hospitalized with decompensated heart failure:evidence for a pediatric cardiorenal syndrome? [J].Pediatr Crit Care Med.2008,9(3):279-284
[28]Rule AD, Bergstralh EJ, Slezak JM, et al.Glomerular filtration rate estimated by cystatin C among different clinical presentations[J].Kidney Int.2006,69:399-405.
[29]Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N latex cystatin C assay on the Dade Behring nephelometer II system[J]. Scand J Clin Lab Invest 1999,59:1-8.
[30]Finney H, Newman DJ, Gruber W, et al. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BNII) [J]. Clin Chem 1997,43:1016-1022.
[31]Young JA, Hwang SJ, Sarnak MJ, et al. Association of visceral and subcutaneous adiposity with kidney function[J]. Clin J Am Soc Nephrol 2008,3:1786-1791.
[32]Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations[J]. J Endocrinol Invest 2005,28:346-349.
[33]Risch L,Herklotz R,Blumberg A,et al.Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients[J]. Clin Chem 2001, 47:2055-2059.
[34]Kottgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States:the Third National Health and Nutrition Examination Survey (NHANES III) [J].Am J Kidney Dis 2008,51:385-394.
[35]Retnakaran R, Connelly PW, Harris SB, et al. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth[J].Pediatr Nephrol.2007,22:1007-1013.
[36]Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States[J]. Am J Med.2008; 121:341-348.
[37]Huo W, Zhang K, Nie Z,et al. Kidney injury molecule-1 (KIM-1):a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury[J]. Transplant Rev.2010,24(3):143-146.
[38]Ichimura T, Bonventre JV, Bailly V,et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury[J]. J Biol Chem. 1998,273:4135-4142.
[39]Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1):a novel biomarker for human renal proximal tubule injury[J]. Kidney Int.2002,62:237-244.
[40]Liangos O, Periyanayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure[J]. J Am Soc Nephrol.2007,18:904-912.
[41]Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers [J].2009; 14:423-431.
[42]Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury[J]. Kidney Int.2008,73:863-869.
[43]van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease[J]. J Pathol.2007,212:209-217.
[44]van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients [J]. Transplantation.2007,84(12):1625-1630.
[45]Waanders F, Vaidya VS, van Goor H, et al. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease:a post hoc analysis of a randomized controlled trial[J]. Am J Kidney Dis.2009,53:16-25.
[46]Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies[J]. Nat Biotechnol.2010,28:478-485.
[47]Vaidya VS, Ford GM, Waikar SS, et al. A rapid urine test for early detection of kidney injury[J]. Kidney Int.2009,76:108-14.
[48]Aure'lien Bataille, Samia Abbas, Oren Semoun. Plasma Neutrophil Gelatinase-Associated Lipocalin in Kidney Transplantation and Early Renal Function Prediction[J]. Transplantation.2011,92:1024-1030
[1]Bagshaw SM, Laupland KB, Doig CJ,Mortis G, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure:a population-based study[J]. Crit Care.2005,9:R700-R709.
[2]Korkeila M, Ruokonen E, Takala J Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care[J]. Intensive Care Med.2000,26:1824-1831
[3]Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients[J]. Crit Care Med.2002, 30:2051-2058
[4]GS Morimatsu H, Morgera S, Schetz M, et al. Acute renal failure in critically ill patients:a multinational, multicenter study[J]. JAMA.2005,294:813-818
[5]Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units[J]. Crit Care.2007,11:R68.
[6]Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries,1992 to 2001[J]. J Am Soc Nephrol.2006,17:1135-1142
[7]Andreoli SP. Acute renal failure[J]. Curr Opin Pediatr.2002,14.183-188
[8]Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure[J]. Pediatr Nephrol.2002,17:61-69
[9]Williams DM, Sreedhar SS, Mickell JJ, et al. Acute kidney failure:a pediatric experience over 20 years. Arch Pediatr Adolesc Med.2002,156:893-900
[10]Vachvanichsanong P, Dissaneewate P, Lim A, et al. Childhood acute renal failure: 22-year experience in a university hospital in southern Thailand[J]. Pediatrics. 2006,118:e786-791
[11]Hui-Stickle S, Brewer ED, Goldstein SL.Pediatric ARF Epidemiology at a Teritary Care Center from 1999 to 2001 [J]. Am J Kidney Dis.2005,45:96-101
[12]Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury[J]. Kidney Int.2007,71:1028-35.
[13]Loza R, Estremadoyro L, Loza C, et al. Factors associated with mortality in acute renal failure (ARF) in children[J]. Pediatr Nephrol.2006,21:106-9.
[14]Olowu WA, Adelusola KA. Pediatric acute renal failure in southwestern Nigeria[J]. Kidney Int.2004,66:1541-8.
[15]Bailey D, Phan V, Litalien C, et al. Risk factors of acute renal failure in critically ill children:a prospective descriptive epidemiological study[J]. Pediatr Crit Care Med.2007,8:29-35.
[16]Gallego N, Perez-Caballero C, Gallego A, et al. Prognosis of patients with acute renal failure without cardiopathy. Arch Dis Child[J].2001,84:258-60.
[17]Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality:A prospective, multicenter study. French Study Group on Acute Renal Failure[J]. Crit Care Med. 1996:192-198.
[18]de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU:Risk factors and outcome evaluated by the SOFA score[J]. Intensive Care Med. 2000:915-921.
[19]Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States[J]. Am J Respir Crit Care Med. 2003:695-701.
[20]Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL):A troponin-like biomarker for human acute kidney injury [J]. Nephrology (Carlton).2010, 15:419-428.
[21]Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens[J].2008,17:127-132
[22]Devarajan P. Update on mechanisms of ischemic acute kidney injury [J]. J Am Soc Nephrol.2006,17:1503-1520.
[23]Murray PT, Devarajan P, Levey AS, et al. A framework and key research questions in AKI diagnosis and staging in different environments [J]. Clin J Am Soc Nephrol. 2008,3:864-868.
[24]Kikkeri D, Pennell JP, Hwang KH, et al. Endotoxemic acute renal failure in awake rats[J]. Am J Physiol.1986,250:F1098-F1106.
[25]Badr KF, Kelley VE, Rennke HG, et al. Roles for thromboxane A2 and leuko trienes in endotoxin-induced acute renal failure[J]. Kidney Int.1986,30:474-480.
[26]Wan L, Bagshaw SM, Langenberg C, et al. Pathophysiology of septic acute kidney injury:what do we really know? [J]. Crit Care Med.2008,36:198-203
Bradley VE, Shier MR, Lucas CE, et al. Renal hemodynamic response to furosemide in septic and injured patients[J]. Surgery.1976,79:549-54.
[28]Di Giantomasso D, Morimatsu H, May CN, et al. Intra-renal blood flow distribution in hyperdynamic septic shock:effect of norepinephrine[J]. Crit Care Med 2003, in press.
[29]Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure[J]. Kidney Int 2006;69:1996-2002.
[30]Chen, S., M. D. Apostolova, et al.Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells [J]. Lab Invest.2000,80(8):1311-1321.
[31]Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin[J]. Science.1986,234:470-4.
[32]Nechemia-Arbely Y, Barkan D, Pizov G, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury[J]. J Am Soc Nephrol 2008;19:1106-15.
[33]Okusawa S, Gelfand JA, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits:synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition[J]. J Clin Invest.1988,81:1162-72.
[34]Chvojka J, Sykora R, Karvunidis T, et al. New developments in septic acute kidney injury[J]. Physiol Res.2010,59:859-69.
[35]Cunningham PN, Dyanov, Park P, et al.:Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney [J]. J Immunol.2002, 168:5817-5823.
[36]Baud L, Oudinet JP, Bens M, et al. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide[J]. Kidney Int.1989, 35:1111-1118.
[37]Karin M, Delhase M. The I-B kinase (IKK) and NF-B:key elements of proinflammatory signalling[J]. Immunology.2000,12:85-98.
[38]Yi-pingWang,GopalaK Rangan, BrayanGoodwin, et al.Lipopolysaccharide induced MCP-1 gene expression in rat tubuler epithelial cells is nuclear factor-kappaB dependent[J].Kidney int.2000,57:2011-2022.
[39]Wang Y, Rangan GK, Goodwin B, et al. Lipopolysaccharide-induced MCP-1 gene expression in rat tubular epithelial cells is nuclear factor-kB dependent[J]. Kidney Int.2000,57:2011-22.
[40]Jonathan Himmelfarb, Ellen McMonagle, Stephanie Freedman.etal. Oxidative Stress Is Increased in Critically Ill Patients with Acute Renal Failure[J]. J Am Soc Nephrol.2004,15:2449-2456.
[41]Sutton TA, Fisher CJ, Molitoris BA.Microvascular endothelial injury and dysfunction during ischemic acute renal failure[J]. Kidney Int.2002,62:539-549.
[42]Hengartner MO. The biochemistry of apoptosis[J]. Nature.2000,407:770-6.
[43]Levine JS, Lieberthal W:Terminal pathways to cell death. In Acute Renal Failure, edn 1. Edited by Molitoris BA, Finn WF[J]. New York:WB Saunders; 2001:30-59.21
[44]Bonegio R, LieberthalW:Role of apoptosis in the pathogenesis of acute renal failure[J]. Curr Opin Nephrol Hypertens.2002,11:301-308.
[45]Saikumar P, Venkatachalam MA. Role of apoptosis in hypoxic/ischemic damage in the kidney[J]. Semin Nephrol.2003,23:511-21.
[46]Guo R, Wang Y, Minto AW, et al. Acute renal failure in endotoxemia is dependent on caspase activation[J]. J Am Soc Nephrol.2004,15:3093-102.
[47]Messmer UK, Briner VA, Pfeilschifter J:Tumour necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells[J]. Kidney Int.1999,55:2322-2337.
[48]Jo SK, Cha DR, Cho WY, et al. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells[J]. Nephron.2002,91:406-415.
[49]D. Nochy. P, Histopathology of septic shock induced acute kidney injury:poptosis and leukocytic infiltration [J]. Intensive Care Med.2010,36:471-478.
[50]殷国庆.感染性休克动物模型研究[D].南京：南京农业大学.2005.
[51]季红,朱晓云,殷国庆.内毒素性休克早期猕猴肾脏超微结构的改变及酶细胞化学观察[J].南京医科大学学报(自然科学版).2008,26(8)：255-259.
[52]谢立平,Sk rezek C,W and H,氨基酸保护肾小管细胞溶酶体功能的研究[D],浙江：浙江大学.2000.
[53]Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury[J]. Pediatr Nephrol.2008,23:2151-2157.
[54]Devarajan P. Emerging biomarkers of acute kidney injury [J]. Contrib Nephrol. 2007,156:203-212.
[55]Devarajan P. Proteomics for biomarker discovery in acute kidney injury[J]. Semin Nephrol.2007,27:637-651.
[56]Devarajan P. Proteomics for the investigation of acute kidney injury[J]. Contrib Nephrol.2008,160:1-16.
[57]Brzin J, Popovic T, Turk V, et al. Human cystatin, a new protein inhibitor of cysteine proteinases[J]. Biochem Biophys Res Commun.1984,118:103-109.
[58]Barrett AJ, DaviesME,Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors [J]. Biochem Biophys Res Commun. 1984,120:631-636.
[59]Grubb AO. Cystatin C:properties and use as diagnostic marker[J]. Adv Clin Chem.2000,35:63-99.
[60]Kaseda R, Iino N, HosojimaM, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells[J]. Biochem Biophys Res Commun.2007; 357:1130-1134.
[61]Herget-Rosenthal S,MarggrafG, Husing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int.2004,66:1115-1122.
[62]16. Bonventre JV. Kidney injury molecule-1 (KTM-1):a urinary biomarker and much more[J]. Nephrol Dial Transplant.2009,24(11):3265-3268.
[63]Huo W, Zhang K, Nie Z, et al. Kidney injury molecule-1 (KIM-1):a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury[J]. Transplant Rev.2010,24(3):143-146.
[64]Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury[J]. J Biol Chem.1998,273:4135-4142.
[65]Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1):a novel biomarker for human renal proximal tubule injury[J]. Kidney Int. 2002,62:237-244.
[66]Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure[J]. J Am Soc Nephrol.2007,18:904-912.
[67]Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers.2009,14:423-431.
[68]Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury [J]. Kidney Int.2008,73:863-869.
[69]van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease[J]. J Pathol.2007,212:209-217.
[70]van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients [J]. Transplantation.2007,84(12):1625-1630.
[71]Waanders F, Vaidya VS, van Goor H, et al. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease:a post hoc analysis of a randomized controlled trial[J]. Am J Kidney Dis.2009,53:16-25.
[72]Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies[J]. Nat Biotechnol.2010,28:478-485.
[73]Vaidya VS, Ford GM, Waikar SS, et al. A rapid urine test for early detection of kidney injury [J]. Kidney Int.2009,76:108-14.
[74]Michael Zappitellil, Kimberly K Washburnl, Ayse A Arikanl,et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children:a prospective cohort study [J]. Critical Care.2007,11(4): R84.
[75]Sean M. Bagshaw, Michael Bennett, Michael Haase, et al. Plasma and urine neutrophil gelatinaseassociated lipocalin in septic versus non-septic acute kidney injury in critical illness[J]. Intensive Care Med.2010,36:452-461
[76]Langenberg C, Bellomo R, May CN, et al. Renal vascular resistance in sepsis[J]. Nephron Physiol.2006,104:1-11.
[77]Molitoris BA. Renal blood flow in sepsis:a complex issue[J]. Crit Care. 2005,9:327-28.
[78]Langenberg C, Wan L, Egi M, et al. Renal blood flow and function during recovery from experimental septic acute kidney injury [J]. Intensive Care Med 2007;33:1614-8.
[79]Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign management guidelines committee:surviving sepsis campaign guidelines for management of severe sepsis and septic shock[J]. Crit Care Med.2004,32:858-73.
[80]Russell JA. Management of sepsis[J]. N Engl J Med.2006,355:1699-713.
[81]Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group:early goal-directed therapy in the treatment of severe sepsis and septic shock[J]. N Engl J Med.2001,345:1368-77
[82]Michard F. Changes in arterial pressure during mechanical ventilation[J]. Anesthesiology.2005,103:419-28, quiz 449-5.
[83]Lin SM, Huang CD, Lin HC, et al. A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock:a randomized controlled trial[J]. Shock.2006,26:551-7.
[84]Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis:a multicentre randomised study [J]. Lancet.2001,357:911-6.
[85]Davidson IJ. Deleterious renal effects of hydroxyethyl starch 130/0.4 and 200/0.5 solutions[J]. Eur J Anaesthesiol.2007,24:892-3.
[86]Boldt J. Renal impact of fluid management with colloids[J]. Eur J Anaesthesiol. 2007,24:891-2.
[87]Finfer S, Bellomo R, Boyce N, et al. SAFE Study Investigators:a comparison of albumin and saline for fluid resuscitation in the intensive care unit[J]. N Engl J Med.2004,350:2247-56.
[88]Barrett LK, Singer M, Clapp LH. Vasopressin:mechanisms of action on the vasculature in health and in septic shock[J]. Crit Care Med.2007,35:33-40.
[89]Russell JA. Vasopressin in vasodilatory and septic shock[J]. Curr Opin Crit Care. 2007,13:383-91
[90]Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock[J]. Anesthesiology.2002,96: 576-82.
[91]Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction:a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group[J]. Lancet.2000, 356:2139-43.
[92]Burton CJ, Tomson CR. Can the use of low-dose dopamine for treatment of acute renal failure be justified? [J]. Postgrad Med J.1999,75:269-74.
[93]Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure:scientific rationale, experimental studies and clinical trials[J]. Kidney Int.1996,50:4-14.
t94] Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure:a controlled trial[J]. Clin Nephrol.1981,15:90-6.
[95]Kleinknecht D, Ganeval D, Gonzalez-Duque LA, Fermanian J. Furosemide in acute oliguric renal failure. A controlled trial[J]. Nephron 1976,17:51-8.
[96]Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure:a prospective, double-blind, placebo-controlled, randomized study [J]. Nephrol Dial Transplant.1997,12:2592-6.
[97]Griffin JH, Fernandez JA, Gale AJ, et al. Activated protein C[J]. J Thromb Haemost.2007,5(Suppl 1):73-80.
[98]Gerlach H, Esposito C, Stern DM. Modulation of endothelial hemostatic properties: an active role in the host response[J]. Annu Rev Med.1990,41:15-24.
[99]Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnor malities in sepsis and its relation to outcome[J], Chest.1993,103:1536-42.
[100]Boldt J, Papsdorf M, Rothe A, et al. Changes of the hemostatic network in critically ill patients-is there a difference between sepsis, trauma, and neurosurgery patients? [J].Crit Care Med.2000,28:445-50.
[1]Andrikos E, Tseke P, Balafa O, et al. Epidemiology of acute renal failure in ICUs:a multi-center prospective study[J]. Blood Purif.2009,28:239-244.
[2]Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis[J]. Hepatology.2008,48:2064-2077.
[3]Khalil P, Murty P, Palevsky PM. The patient with acute kidney injury[J]. Prim Care.2008,35:239-264.
[4]Chawla LS, Abell L, Mazhari R, et al. Identifying critically ill patients at high risk for developing acute renal failure:A pilot study[J]. Kidney Int.2005,68:2274-2280.
[5]Macedo E, Castro I, Yu L,et al. Impact of mild acute kidney injury (AKI) on outcome after open repair of aortic aneurysms[J]. Ren Fail.2008,30:287-296.
[6]Rosner MH, Okusa MD. Acute kidney injury associated withcardiac surgery [J]. Clin J Am Soc Nephrol.2006,1:19-32.
[7]Byers J, Sladen RN. Renal function and dysfunction[J]. Curr Opin Anaesthesiol. 2001,14:699-706.
[8]Schrier RW, Wang W. Acute renal failure and sepsis[J]. N Engl J Med. 2004,351:159-169.
吲段绍斌,刘伏友,彭佑铭,等.造影剂对慢性肾功能不全患者肾毒性[J].肾脏病与透析肾移植杂志.2001,10：130-132.
[10]Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism:A recognizable cause of renal disease[J]. Am J Kidney Dis.2000,36:1089-1109.
[11]Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology,clinical consequences, and treatment of tumor lysis syndrome[J]. Am J Med.2004,116:546-554.
[12]Modi KS, Rao VK. Atheroembolic renal disease[J]. J Am Soc Nephrol.2001,12: 1781-1787.
[13]Seabra VF, Balk EM, Liangos O, et al. Timing of renal replacement therapy initiation in acute renal failure:A meta-analysis[J].Am J Kidney Dis. 2008,52:272-284.
[14]Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure:a prospective, randomized trial[J]. Crit Care Med.2002,30:2205-2211.
[15]Cho KC, Himmelfarb J, Paganini E, et al. Survival by dialysis modality in critically ill patients with acute kidney injury[J]. J Am Soc Nephrol. 2006,17:3132-3138.
[16]王质刚.杂合肾脏替代概念及发展前景[J].中国血液净化,2009,12：639-643.
[17]Kumar VA, Yeun JY, Depner TA,et al. Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure:a two-year single center report[J]. Int J Artif Organs.2004,27:371-379.
[18]Saudan P, Niederberger M, De Seigneux S, et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure[J]. Kidney Int.2006,70:1312-1317.
[19]Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury[J]. N Engl J Med.2008,359:7-20.
P1 Levy MM, Fink MP, Marshall JC, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference[J]. Crit Care Med.2003,31:1250-1256.
[3]Martin GS,Mannino DM,Eaton S,et al. The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med 2003,348(16):1546-1554.
[4]Vincent JL,Sakr Y Sprung CL,et al. Sepsis in European intensive care units:Results of the SOAP study[J]. Crit Care Med 2006,34(2):344-353.
[5]Adfie C, Alberti C, Chaix-Couturier C,et al. Epidemiology and economic evaluation of severe sepsis in France:age, severity,infection site, and place of acquisition(community, hospital or intensive care unit as determinants of workload and cost[J]. J Crit Care 2005,20:46-58.
[6]Sushma K,Cribbs,Greg S et al. Expanding the global epidemiology of sepsis[J]. Cfit Care Med.2007,35(11):2646-2648.
[7]Angus DC,Linde-Zwirble WT,Lidicker J,et al. Epidemiology of severe sepsis in the United States:analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med.2001,29:1303-1310.
[8]Silva E, Pedro MA, Sogaya ACB, et al:Brazilian Sepsis Epidemiological Study (BASES study) [J]. Crit Care 2004,8(4):R251-R260.
[9]Sundarrarajan V, Korman Z, Visvanathan K,et al. The microbiology and outcome of sepsis in Victoria,Australia[J]. Epidemiol Infect,2005,000:1-8.
[10]Finfer S,Bellomo L, Lipman J,et al. Adult population incidence of severe sepsis in Australia and New Zealand intensive care units[J]. Intensive Care Med.2004,30: 589-596
[11]Padkin A,Goldfrad C,Brady AR,et al. Epidemiology of severe sepsis occ urring in the first 24h in intensive care units in England, Wales and Northern Ireland[J]. Crit Care Med.2003,31:2332-2338.
[12]Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults:A multicenter prospective study in intensive care units[J]. JAMA.1995,274:968-974.
[131林洪远,盛志勇.我们需要一个更清晰的脓毒症概念和标准[J].中华外科杂志.2004,42：836-838.
[14]黎沾良.全身炎症反应综合征和多器官功能障碍综合征[J].中国实用外科杂志.1999,19(1)：36-37.
[15]柴家科,盛志勇,郭振荣等.不同治疗阶段(1970～1998年)烧伤脓毒症的防治经验[J].中华烧伤杂志.2000,16(2)：78-81.
[16]代静泓,邱海波,杨毅等.1991-2001年ICU严重感染的流行病学调查分析[J].中华老年多器官杂志.2003,2：42-46.
[17]Cheng B,Xie G Yao S,et al. Epidemiology of Severe Sepsis in Critically ill Surgical Patients in 10 University Hospitals in China[J]. Crit Care Med.2007, 35(11):2538-2546.
[18]Goldstein B,Gimir B,Randolph A,et al. International pediatric sepsis consensus conference:definitions for sepsis and organ dysfunction in pediatrics[J].Pediatric Crit Care Med.2005,6:2-8.
[19]Hayden WR. Sepsis terminology in pediatrics[J].J Pediatr.1994,124:657-658.
[20]樊寻梅,武志远.国际儿科脓毒症定义会议介绍[J].中华儿科学,2005,43：618-620.
[21]喻文亮,陆铸今,孙波.小儿、新生儿全身炎症反应综合征、脓毒症及感染性休克新定义[J].中国小儿急救医学.2006,13：1-4.
[22]R Scott Watson, Joseph, A Carcillo Walter, et al.The Epidemiology of Severe Sepsis in Children in the United States[J].Am J Resp and Crit Care Med.2003, 167:695-701.
[23]王嵩,王义,郭纪元.儿童重症监护病房脓毒症患病现状调查分析[J].陕西医学杂志[J].2009.38(1)：112-3
[24]上海ICU脓毒症诊治情况调查协作组.上海市四家儿童医院重症监护病房304例脓毒症诊治调查分析[J].中华儿科杂志,2012,50(3)：172-177。
[25]中华医学会儿科分会急诊学组.第四届全国小儿急救医学研讨会纪要[J].中华儿科杂志,1995,33：370-373
[26]WY Kim, JW Huh, CM Lim et al.A Comparison of Acute Kidney Injury Classifications in Patients With Severe Sepsis and Septic Shock[J].Am J Med Sci. 2012 Jan 18. [Epub ahead of print]
[1]Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure:a population-based study. Crit Care[J].2005,9:R700-R709.
[2]Korkeila M, Ruokonen E, Takala J.Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care[J]. Intensive Care Med.2000,26:1824-1831
[3]Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients[J]. Crit Care Med.2002, 30:2051-2058.
[4]GS, Morimatsu H, Morgera S, Schetz M, et al. Acute renal failure in critically ill patients:a multinational, multicenter study[J]. JAMA.2005,294:813-818.
[5]Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units[J]. Crit Care 2007,11:R68,1-9.
[6]Xue JL, Daniels F, Star RA,et al. Incidence and mortality of acute renal failure in Medicare beneficiaries,1992 to 2001[J]. J Am Soc Nephrol.2006,17:1135-1142.
[7]Vachvanichsanong P, Dissaneewate P, Lim A, Mcneil E. Childhood acute renal failure:22-year experience in a university hospital in southern Thailand. Pediatrics. 2006;118(3):e786-791.
[8]Andreoli SP. Acute renal failure [J]. Curr Opin Pediatr.2002,14:183-188.
[91 Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure[J]. Pediatr Nephrol.2002,17:61-69.
[10]Williams DM, Sreedhar SS, Mickell JJ, et al. Acute kidney failure:a pediatric experience over 20 years[J]. Arch Pediatr Adolesc Med.2002,156:893-900.
[11]Hui-Stickle S, Brewer ED, Goldstein SL.Pediatric ARF Epidemiology at a Teritary Care Center from 1999 to 2001 [J]. Am J Kidney Dis.2005,45:96-101.
[12]Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury[J]. Kidney Int.2007,71:1028-35.
[13]Loza R, Estremadoyro L, Loza C, et al. Factors associated with mortality in acute renal failure (ARF) in children[J]. Pediatr Nephrol.2006,21:106-9.
[14]Olowu WA, Adelusola KA. Pediatric acute renal failure in southwestern Nigeria[J]. Kidney Int.2004,66:1541-8.
[15]Bailey D, Phan V, Litalien C, et al. Risk factors of acute renal failure in critically ill children:a prospective descriptive epidemiological study [J]. Pediatr Crit Care Med.2007,8:29-35.
[16]Gallego N, Perez-Caballero C, Gallego A, et al. Prognosis of patients with acute renal failure without cardiopathy[J]. Arch Dis Child.2001,84:258-60.
[17]Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality:A prospective, multicenter study. French Study Group on Acute Renal Failure[J]. Crit Care Med. 1996:192-198.
[18]de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU:Risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000:915-921.
[19]Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States[J]. Am J Respir Crit Care Med. 2003:695-701.
[40]Bagshaw SM, George C, Dinu I,Bellomo R. A multi-centre evaluation of the Rifle criteria for early acute kidney injury in critically ill patients[J].Nephrol Dial Transplant 2008,23:1203-1210.
[21]Ostermann M, Chang RW. Acute kidney injury in the intensive care unit ACCording to RIFLE[J]. Crit Care Med.2007,35:1837-1843.
[22]Bagshaw SM, Uehino S, Bellomo R, etl.Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators:Septic acute kidney injury in critically ill patients:clinical characteristics and outcomes[J]. Clin J Am Soc Nephrol.2007,2:431-439.
[23]Lameire N, VanBiesen W, Vanholder R. Acute renal failure[J]. lancet.2005,365: 417-430.
[24]Edelstein, CL. Schrier, RW. Pathophysiology of ischemic acute renal failure[J]. In: Schrier, RW., editor.Diseases of the kidney and urinary tract.7. Vol.2. Philadelphia: Lippincott Williams & Wilkins; 2001. p1041-69.
[25]杨荣利,王小亭,刘大为.感染性休克致急性肾损伤的血流动力学特征及对预后的意义,中华内科杂志[J].2009,9：715-719.
[26]Devarajan P. Emerging biomarkers of acute kidney injury[J]. Contrib Nephrol. 2007:203-212.
[27]Goldstein SL, Currier H, Graf JM, et al. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics[J].2001:1309-1312.
[28]Goldstein SL, Somers MJG, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy [J]. Kidney Int.2005:653-658.
[29]Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children:A retrospective analysis [J]. Crit Care Med.2004:1771-1776.
[30]Lowrie LH. Renal replacement therapies in pediatric multi-organ dysfunction syndrome[J]. Pediatr Nephrol.2000:6-12.
[31]Bellomo R, Bagshaw S, Langenberg C, et al. Pre-renal azotemia:a flawed paradigm in critically ill septic patients? [J].Contrib Nephrol.2007,156:1-9
[32]Langenberg C, Wan L, Bagshaw SM, et al.Urinary biochemistry in experimental septic acute renal failure. Nephrol Dial Transplant [J].2006,21:3389-3397.
[33]Langenberg C,Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure[J].Kidney Int.2006,69:1996-2002.
[34]Licari E, Calzava P, Ronco C. Bellomo R.Fluid resuscitation and the septic kidney: the evidence[J].Contrib Nephrol.2007,156:167-177.
[35]刘娟,钱素云.小儿脓毒症和严重脓毒症发病情况单中心调查[J].2010,28(1)：26-29.
[35]Venkatachalam MA, Griffin KA, Lan R,et al. Acute kidney injury:a springboard for progression in chronic kidney disease [J]. Am J Physiol Renal Physiol.2010, 298:F1078-F1094.
[37]Askenazi DJ, Feig DI, Graham NM, et al.3-5 year longitudinal follow-up of pediatric patients after acute renal failure[J]. Kidney Int.2006,69:184-189.
[38]Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network:report of an initiative to improve outcomes in acute kidney injury[J]. Crit Care.2007,11:R31
[39]Bellomo R, Ronco C, Kellum JA, et al. Acute Dialysis Quality Initiative Workgroup:Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs [J]. Crit Care.2004,8:R204-R212.
[40]WY Kim, JW Huh, CM Lim et al.A Comparison of Acute Kidney Injury Classifications in Patients With Severe Sepsis and Septic Shock[J].Am J Med Sci. 2012 Jan 18,R700-R709.
[41]Bagshaw, S. M., S. Lapinsky, et al. Acute kidney injury in septic shock:clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy[J]. Intensive Care Med.2009,35(5):871-881.
[42]Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States:analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med.2001,29:1303-1310
[43]Martin GS, Mannino DM, Eaton S, et al.The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med.2003,348:1546-1554
[44]Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS:a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units[J]. Intensive Care Med.2004,30:580-588
[45]Lopes JA, Jorge S, Resina C, et al. Acute renal failure in patients with sepsis[J]. Crit Care.2007,11:411
[46]Yegenaga I, Hoste E, Van Biesen W, et al. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome:results of a prospective study[J]. Am J Kidney Dis.2004,43:817-824
[47]Hoste EA, Lameire NH, Vanholder RC,et al. Acute renal failure in patients with sepsis in a surgical ICU:predictive factors, incidence, comorbidity, and outcome[J]. J Am Soc Nephrol.2003,14:1022-1030
[48]Vincent JL, Sakr Y, Sprung CL, et al.Sepsis in European intensive care units: results of the SOAP study[J]. Crit Care Med.2006,34:344-353
[49]Oppert M, Engel C, Brunkhorst FM, et al.Acute renal failure in patients with severe sepsis and septic shock a significant independent risk factor for mortality: results from the German Prevalence Study [J]. Nephrol Dial Transplant.2008, 23:904-909
[50]Neveu H, Kleinknecht D, Brivet F, et al. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure[J]. Nephrol Dial Transplant.1996,11-.293-299
[1]Schneider J, Khemani R, Grushkin C, et al. Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit[J]. Crit Care Med.2010, 38:933-939.
[2]Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury [J]. Kidney Int.2007,71:1028-1035.
[3]Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL):A troponin-like biomarker for human acute kidney injury[J]. Nephrology (Carlton).2010, 15:419-428.
[4]Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease[J]. Curr Opin Nephrol Hypertens.2008,17:127-132
[5]Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol.2006,17:1503-1520.
[6]Murray PT, Devarajan P, Levey AS, et al. A framework and key research questions in AKI diagnosis and staging in different environments[J]. Clin J Am Soc Nephrol. 2008,3:864-868.
[7]Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics[J]. Kidney Int.1985,928-937.
[8]Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury[J]. Pediatr Nephrol.2008,23:2151-2157.
[9]Devarajan P. Emerging biomarkers of acute kidney injury[J], Contrib Nephrol. 2007,156:203-212.
[10]Devarajan P. Proteomics for biomarker discovery in acute kidney injury[J]. Semin Nephrol.2007,27:637-651.
[11]Devarajan P. Proteomics for the investigation of acute kidney injury[J]. Contrib Nephrol.2008,160:1-16.
[12]Prasad Devarajan. Biomarkers for the Early Detection of Acute Kidney Injury[J]. Curr Opin Pediatr.2011,23(2):194-200
[13]Brzin J, Popovic T, Turk V, et al. Human cystatin, a new protein inhibitor of cysteine proteinases[J]. Biochem Biophys Res Commun 1984,118:103-109.
[14]Barrett AJ, DaviesME,Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors[J]. Biochem Biophys Res Commun. 1984,120:631-636.
[15]Grubb AO. Cystatin C:properties and use as diagnostic marker[J]. Adv Clin Chem.2000,35:63-99.
[16]Kaseda R, Iino N, HosojimaM, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells[J]. Biochem Biophys Res Commun 2007,357:1130-1134.
[17]Herget-Rosenthal S,MarggrafG, Husing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int 2004,66:1115-1122.
[18]Bonventre JV. Kidney injury molecule-1 (KIM-1):a urinary biomarker and much more[J]. Nephrol Dial Transplant.2009,24(11):3265-3268.
[19]Michael Zappitellil, Kimberly K Washburnl, Ayse A Arikanl,et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children:a prospective cohort study[J].Critical Care,11(4):R84.
[20]Sean M. Bagshaw, Michael Bennett, Michael Haase et al.Plasma and urine neutrophil gelatinaseassociated lipocalin in septic versus non-septic acute kidney injury in critical illness[J].Intensive Care Med,2010,36:452-461
[21]Neveu H, Kleinknecht D, Brivet F,, et al. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The french study group on acute renal failure[J]. Nephrol Dial Transplant.1996,11:293-299
[22]Uchino S, Kellum JA, Bellomo R, et al.Acute renal failure in critically ill patients: a multinational, multicenter study[J]. JAMA,2005 294:813-818
[23]Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis:a multicentre evaluation[J]. Crit Care.2008,12:R47
[24]Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients:clinical characteristics and outcomes[J]. Clin J Am Soc Nephrol 2007,2:431-439
[25]Wan L, Bagshaw SM, Langenberg C, et al. Pathophysiology of septic acute kidney injury:what do we really know? [J].Crit Care Med.2008,36:S198-S203
[26]Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay and costs in hospitalized patients[J]. J Am Soc Nephrol.2005, 16:3365-3370.
[27]Price, J. F., A. R. Mott, et al. Worsening renal function in children hospitalized with decompensated heart failure:evidence for a pediatric cardiorenal syndrome? [J].Pediatr Crit Care Med.2008,9(3):279-284
[28]Rule AD, Bergstralh EJ, Slezak JM, et al.Glomerular filtration rate estimated by cystatin C among different clinical presentations[J].Kidney Int.2006,69:399-405.
[29]Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N latex cystatin C assay on the Dade Behring nephelometer II system[J]. Scand J Clin Lab Invest 1999,59:1-8.
[30]Finney H, Newman DJ, Gruber W, et al. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BNII) [J]. Clin Chem 1997,43:1016-1022.
[31]Young JA, Hwang SJ, Sarnak MJ, et al. Association of visceral and subcutaneous adiposity with kidney function[J]. Clin J Am Soc Nephrol 2008,3:1786-1791.
[32]Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations[J]. J Endocrinol Invest 2005,28:346-349.
[33]Risch L,Herklotz R,Blumberg A,et al.Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients[J]. Clin Chem 2001, 47:2055-2059.
[34]Kottgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States:the Third National Health and Nutrition Examination Survey (NHANES III) [J].Am J Kidney Dis 2008,51:385-394.
[35]Retnakaran R, Connelly PW, Harris SB, et al. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth[J].Pediatr Nephrol.2007,22:1007-1013.
[36]Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States[J]. Am J Med.2008; 121:341-348.
[37]Huo W, Zhang K, Nie Z,et al. Kidney injury molecule-1 (KIM-1):a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury[J]. Transplant Rev.2010,24(3):143-146.
[38]Ichimura T, Bonventre JV, Bailly V,et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury[J]. J Biol Chem. 1998,273:4135-4142.
[39]Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1):a novel biomarker for human renal proximal tubule injury[J]. Kidney Int.2002,62:237-244.
[40]Liangos O, Periyanayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure[J]. J Am Soc Nephrol.2007,18:904-912.
[41]Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers [J].2009; 14:423-431.
[42]Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury[J]. Kidney Int.2008,73:863-869.
[43]van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease[J]. J Pathol.2007,212:209-217.
[44]van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients [J]. Transplantation.2007,84(12):1625-1630.
[45]Waanders F, Vaidya VS, van Goor H, et al. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease:a post hoc analysis of a randomized controlled trial[J]. Am J Kidney Dis.2009,53:16-25.
[46]Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies[J]. Nat Biotechnol.2010,28:478-485.
[47]Vaidya VS, Ford GM, Waikar SS, et al. A rapid urine test for early detection of kidney injury[J]. Kidney Int.2009,76:108-14.
[48]Aure'lien Bataille, Samia Abbas, Oren Semoun. Plasma Neutrophil Gelatinase-Associated Lipocalin in Kidney Transplantation and Early Renal Function Prediction[J]. Transplantation.2011,92:1024-1030
[1]Bagshaw SM, Laupland KB, Doig CJ,Mortis G, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure:a population-based study[J]. Crit Care.2005,9:R700-R709.
[2]Korkeila M, Ruokonen E, Takala J Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care[J]. Intensive Care Med.2000,26:1824-1831
[3]Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients[J]. Crit Care Med.2002, 30:2051-2058
[4]GS Morimatsu H, Morgera S, Schetz M, et al. Acute renal failure in critically ill patients:a multinational, multicenter study[J]. JAMA.2005,294:813-818
[5]Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units[J]. Crit Care.2007,11:R68.
[6]Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries,1992 to 2001[J]. J Am Soc Nephrol.2006,17:1135-1142
[7]Andreoli SP. Acute renal failure[J]. Curr Opin Pediatr.2002,14.183-188
[8]Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure[J]. Pediatr Nephrol.2002,17:61-69
[9]Williams DM, Sreedhar SS, Mickell JJ, et al. Acute kidney failure:a pediatric experience over 20 years. Arch Pediatr Adolesc Med.2002,156:893-900
[10]Vachvanichsanong P, Dissaneewate P, Lim A, et al. Childhood acute renal failure: 22-year experience in a university hospital in southern Thailand[J]. Pediatrics. 2006,118:e786-791
[11]Hui-Stickle S, Brewer ED, Goldstein SL.Pediatric ARF Epidemiology at a Teritary Care Center from 1999 to 2001 [J]. Am J Kidney Dis.2005,45:96-101
[12]Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury[J]. Kidney Int.2007,71:1028-35.
[13]Loza R, Estremadoyro L, Loza C, et al. Factors associated with mortality in acute renal failure (ARF) in children[J]. Pediatr Nephrol.2006,21:106-9.
[14]Olowu WA, Adelusola KA. Pediatric acute renal failure in southwestern Nigeria[J]. Kidney Int.2004,66:1541-8.
[15]Bailey D, Phan V, Litalien C, et al. Risk factors of acute renal failure in critically ill children:a prospective descriptive epidemiological study[J]. Pediatr Crit Care Med.2007,8:29-35.
[16]Gallego N, Perez-Caballero C, Gallego A, et al. Prognosis of patients with acute renal failure without cardiopathy. Arch Dis Child[J].2001,84:258-60.
[17]Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality:A prospective, multicenter study. French Study Group on Acute Renal Failure[J]. Crit Care Med. 1996:192-198.
[18]de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU:Risk factors and outcome evaluated by the SOFA score[J]. Intensive Care Med. 2000:915-921.
[19]Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States[J]. Am J Respir Crit Care Med. 2003:695-701.
[20]Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL):A troponin-like biomarker for human acute kidney injury [J]. Nephrology (Carlton).2010, 15:419-428.
[21]Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens[J].2008,17:127-132
[22]Devarajan P. Update on mechanisms of ischemic acute kidney injury [J]. J Am Soc Nephrol.2006,17:1503-1520.
[23]Murray PT, Devarajan P, Levey AS, et al. A framework and key research questions in AKI diagnosis and staging in different environments [J]. Clin J Am Soc Nephrol. 2008,3:864-868.
[24]Kikkeri D, Pennell JP, Hwang KH, et al. Endotoxemic acute renal failure in awake rats[J]. Am J Physiol.1986,250:F1098-F1106.
[25]Badr KF, Kelley VE, Rennke HG, et al. Roles for thromboxane A2 and leuko trienes in endotoxin-induced acute renal failure[J]. Kidney Int.1986,30:474-480.
[26]Wan L, Bagshaw SM, Langenberg C, et al. Pathophysiology of septic acute kidney injury:what do we really know? [J]. Crit Care Med.2008,36:198-203
Bradley VE, Shier MR, Lucas CE, et al. Renal hemodynamic response to furosemide in septic and injured patients[J]. Surgery.1976,79:549-54.
[28]Di Giantomasso D, Morimatsu H, May CN, et al. Intra-renal blood flow distribution in hyperdynamic septic shock:effect of norepinephrine[J]. Crit Care Med 2003, in press.
[29]Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure[J]. Kidney Int 2006;69:1996-2002.
[30]Chen, S., M. D. Apostolova, et al.Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells [J]. Lab Invest.2000,80(8):1311-1321.
[31]Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin[J]. Science.1986,234:470-4.
[32]Nechemia-Arbely Y, Barkan D, Pizov G, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury[J]. J Am Soc Nephrol 2008;19:1106-15.
[33]Okusawa S, Gelfand JA, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits:synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition[J]. J Clin Invest.1988,81:1162-72.
[34]Chvojka J, Sykora R, Karvunidis T, et al. New developments in septic acute kidney injury[J]. Physiol Res.2010,59:859-69.
[35]Cunningham PN, Dyanov, Park P, et al.:Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney [J]. J Immunol.2002, 168:5817-5823.
[36]Baud L, Oudinet JP, Bens M, et al. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide[J]. Kidney Int.1989, 35:1111-1118.
[37]Karin M, Delhase M. The I-B kinase (IKK) and NF-B:key elements of proinflammatory signalling[J]. Immunology.2000,12:85-98.
[38]Yi-pingWang,GopalaK Rangan, BrayanGoodwin, et al.Lipopolysaccharide induced MCP-1 gene expression in rat tubuler epithelial cells is nuclear factor-kappaB dependent[J].Kidney int.2000,57:2011-2022.
[39]Wang Y, Rangan GK, Goodwin B, et al. Lipopolysaccharide-induced MCP-1 gene expression in rat tubular epithelial cells is nuclear factor-kB dependent[J]. Kidney Int.2000,57:2011-22.
[40]Jonathan Himmelfarb, Ellen McMonagle, Stephanie Freedman.etal. Oxidative Stress Is Increased in Critically Ill Patients with Acute Renal Failure[J]. J Am Soc Nephrol.2004,15:2449-2456.
[41]Sutton TA, Fisher CJ, Molitoris BA.Microvascular endothelial injury and dysfunction during ischemic acute renal failure[J]. Kidney Int.2002,62:539-549.
[42]Hengartner MO. The biochemistry of apoptosis[J]. Nature.2000,407:770-6.
[43]Levine JS, Lieberthal W:Terminal pathways to cell death. In Acute Renal Failure, edn 1. Edited by Molitoris BA, Finn WF[J]. New York:WB Saunders; 2001:30-59.21
[44]Bonegio R, LieberthalW:Role of apoptosis in the pathogenesis of acute renal failure[J]. Curr Opin Nephrol Hypertens.2002,11:301-308.
[45]Saikumar P, Venkatachalam MA. Role of apoptosis in hypoxic/ischemic damage in the kidney[J]. Semin Nephrol.2003,23:511-21.
[46]Guo R, Wang Y, Minto AW, et al. Acute renal failure in endotoxemia is dependent on caspase activation[J]. J Am Soc Nephrol.2004,15:3093-102.
[47]Messmer UK, Briner VA, Pfeilschifter J:Tumour necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells[J]. Kidney Int.1999,55:2322-2337.
[48]Jo SK, Cha DR, Cho WY, et al. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells[J]. Nephron.2002,91:406-415.
[49]D. Nochy. P, Histopathology of septic shock induced acute kidney injury:poptosis and leukocytic infiltration [J]. Intensive Care Med.2010,36:471-478.
[50]殷国庆.感染性休克动物模型研究[D].南京：南京农业大学.2005.
[51]季红,朱晓云,殷国庆.内毒素性休克早期猕猴肾脏超微结构的改变及酶细胞化学观察[J].南京医科大学学报(自然科学版).2008,26(8)：255-259.
[52]谢立平,Sk rezek C,W and H,氨基酸保护肾小管细胞溶酶体功能的研究[D],浙江：浙江大学.2000.
[53]Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury[J]. Pediatr Nephrol.2008,23:2151-2157.
[54]Devarajan P. Emerging biomarkers of acute kidney injury [J]. Contrib Nephrol. 2007,156:203-212.
[55]Devarajan P. Proteomics for biomarker discovery in acute kidney injury[J]. Semin Nephrol.2007,27:637-651.
[56]Devarajan P. Proteomics for the investigation of acute kidney injury[J]. Contrib Nephrol.2008,160:1-16.
[57]Brzin J, Popovic T, Turk V, et al. Human cystatin, a new protein inhibitor of cysteine proteinases[J]. Biochem Biophys Res Commun.1984,118:103-109.
[58]Barrett AJ, DaviesME,Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors [J]. Biochem Biophys Res Commun. 1984,120:631-636.
[59]Grubb AO. Cystatin C:properties and use as diagnostic marker[J]. Adv Clin Chem.2000,35:63-99.
[60]Kaseda R, Iino N, HosojimaM, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells[J]. Biochem Biophys Res Commun.2007; 357:1130-1134.
[61]Herget-Rosenthal S,MarggrafG, Husing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int.2004,66:1115-1122.
[62]16. Bonventre JV. Kidney injury molecule-1 (KTM-1):a urinary biomarker and much more[J]. Nephrol Dial Transplant.2009,24(11):3265-3268.
[63]Huo W, Zhang K, Nie Z, et al. Kidney injury molecule-1 (KIM-1):a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury[J]. Transplant Rev.2010,24(3):143-146.
[64]Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury[J]. J Biol Chem.1998,273:4135-4142.
[65]Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1):a novel biomarker for human renal proximal tubule injury[J]. Kidney Int. 2002,62:237-244.
[66]Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure[J]. J Am Soc Nephrol.2007,18:904-912.
[67]Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers.2009,14:423-431.
[68]Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury [J]. Kidney Int.2008,73:863-869.
[69]van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease[J]. J Pathol.2007,212:209-217.
[70]van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients [J]. Transplantation.2007,84(12):1625-1630.
[71]Waanders F, Vaidya VS, van Goor H, et al. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease:a post hoc analysis of a randomized controlled trial[J]. Am J Kidney Dis.2009,53:16-25.
[72]Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies[J]. Nat Biotechnol.2010,28:478-485.
[73]Vaidya VS, Ford GM, Waikar SS, et al. A rapid urine test for early detection of kidney injury [J]. Kidney Int.2009,76:108-14.
[74]Michael Zappitellil, Kimberly K Washburnl, Ayse A Arikanl,et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children:a prospective cohort study [J]. Critical Care.2007,11(4): R84.
[75]Sean M. Bagshaw, Michael Bennett, Michael Haase, et al. Plasma and urine neutrophil gelatinaseassociated lipocalin in septic versus non-septic acute kidney injury in critical illness[J]. Intensive Care Med.2010,36:452-461
[76]Langenberg C, Bellomo R, May CN, et al. Renal vascular resistance in sepsis[J]. Nephron Physiol.2006,104:1-11.
[77]Molitoris BA. Renal blood flow in sepsis:a complex issue[J]. Crit Care. 2005,9:327-28.
[78]Langenberg C, Wan L, Egi M, et al. Renal blood flow and function during recovery from experimental septic acute kidney injury [J]. Intensive Care Med 2007;33:1614-8.
[79]Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign management guidelines committee:surviving sepsis campaign guidelines for management of severe sepsis and septic shock[J]. Crit Care Med.2004,32:858-73.
[80]Russell JA. Management of sepsis[J]. N Engl J Med.2006,355:1699-713.
[81]Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group:early goal-directed therapy in the treatment of severe sepsis and septic shock[J]. N Engl J Med.2001,345:1368-77
[82]Michard F. Changes in arterial pressure during mechanical ventilation[J]. Anesthesiology.2005,103:419-28, quiz 449-5.
[83]Lin SM, Huang CD, Lin HC, et al. A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock:a randomized controlled trial[J]. Shock.2006,26:551-7.
[84]Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis:a multicentre randomised study [J]. Lancet.2001,357:911-6.
[85]Davidson IJ. Deleterious renal effects of hydroxyethyl starch 130/0.4 and 200/0.5 solutions[J]. Eur J Anaesthesiol.2007,24:892-3.
[86]Boldt J. Renal impact of fluid management with colloids[J]. Eur J Anaesthesiol. 2007,24:891-2.
[87]Finfer S, Bellomo R, Boyce N, et al. SAFE Study Investigators:a comparison of albumin and saline for fluid resuscitation in the intensive care unit[J]. N Engl J Med.2004,350:2247-56.
[88]Barrett LK, Singer M, Clapp LH. Vasopressin:mechanisms of action on the vasculature in health and in septic shock[J]. Crit Care Med.2007,35:33-40.
[89]Russell JA. Vasopressin in vasodilatory and septic shock[J]. Curr Opin Crit Care. 2007,13:383-91
[90]Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock[J]. Anesthesiology.2002,96: 576-82.
[91]Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction:a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group[J]. Lancet.2000, 356:2139-43.
[92]Burton CJ, Tomson CR. Can the use of low-dose dopamine for treatment of acute renal failure be justified? [J]. Postgrad Med J.1999,75:269-74.
[93]Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure:scientific rationale, experimental studies and clinical trials[J]. Kidney Int.1996,50:4-14.
t94] Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure:a controlled trial[J]. Clin Nephrol.1981,15:90-6.
[95]Kleinknecht D, Ganeval D, Gonzalez-Duque LA, Fermanian J. Furosemide in acute oliguric renal failure. A controlled trial[J]. Nephron 1976,17:51-8.
[96]Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure:a prospective, double-blind, placebo-controlled, randomized study [J]. Nephrol Dial Transplant.1997,12:2592-6.
[97]Griffin JH, Fernandez JA, Gale AJ, et al. Activated protein C[J]. J Thromb Haemost.2007,5(Suppl 1):73-80.
[98]Gerlach H, Esposito C, Stern DM. Modulation of endothelial hemostatic properties: an active role in the host response[J]. Annu Rev Med.1990,41:15-24.
[99]Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnor malities in sepsis and its relation to outcome[J], Chest.1993,103:1536-42.
[100]Boldt J, Papsdorf M, Rothe A, et al. Changes of the hemostatic network in critically ill patients-is there a difference between sepsis, trauma, and neurosurgery patients? [J].Crit Care Med.2000,28:445-50.
[1]Andrikos E, Tseke P, Balafa O, et al. Epidemiology of acute renal failure in ICUs:a multi-center prospective study[J]. Blood Purif.2009,28:239-244.
[2]Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis[J]. Hepatology.2008,48:2064-2077.
[3]Khalil P, Murty P, Palevsky PM. The patient with acute kidney injury[J]. Prim Care.2008,35:239-264.
[4]Chawla LS, Abell L, Mazhari R, et al. Identifying critically ill patients at high risk for developing acute renal failure:A pilot study[J]. Kidney Int.2005,68:2274-2280.
[5]Macedo E, Castro I, Yu L,et al. Impact of mild acute kidney injury (AKI) on outcome after open repair of aortic aneurysms[J]. Ren Fail.2008,30:287-296.
[6]Rosner MH, Okusa MD. Acute kidney injury associated withcardiac surgery [J]. Clin J Am Soc Nephrol.2006,1:19-32.
[7]Byers J, Sladen RN. Renal function and dysfunction[J]. Curr Opin Anaesthesiol. 2001,14:699-706.
[8]Schrier RW, Wang W. Acute renal failure and sepsis[J]. N Engl J Med. 2004,351:159-169.
吲段绍斌,刘伏友,彭佑铭,等.造影剂对慢性肾功能不全患者肾毒性[J].肾脏病与透析肾移植杂志.2001,10：130-132.
[10]Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism:A recognizable cause of renal disease[J]. Am J Kidney Dis.2000,36:1089-1109.
[11]Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology,clinical consequences, and treatment of tumor lysis syndrome[J]. Am J Med.2004,116:546-554.
[12]Modi KS, Rao VK. Atheroembolic renal disease[J]. J Am Soc Nephrol.2001,12: 1781-1787.
[13]Seabra VF, Balk EM, Liangos O, et al. Timing of renal replacement therapy initiation in acute renal failure:A meta-analysis[J].Am J Kidney Dis. 2008,52:272-284.
[14]Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure:a prospective, randomized trial[J]. Crit Care Med.2002,30:2205-2211.
[15]Cho KC, Himmelfarb J, Paganini E, et al. Survival by dialysis modality in critically ill patients with acute kidney injury[J]. J Am Soc Nephrol. 2006,17:3132-3138.
[16]王质刚.杂合肾脏替代概念及发展前景[J].中国血液净化,2009,12：639-643.
[17]Kumar VA, Yeun JY, Depner TA,et al. Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure:a two-year single center report[J]. Int J Artif Organs.2004,27:371-379.
[18]Saudan P, Niederberger M, De Seigneux S, et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure[J]. Kidney Int.2006,70:1312-1317.
[19]Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury[J]. N Engl J Med.2008,359:7-20.